Kohortenstudie
Comparative Outcomes of Rifaximin Monotherapy and Lactulose in Cirrhosis: A Multicenter Cohort Study
Gut and Liver · 24.07.2026
DOI: 10.5009/gnl260099 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Gut and Liver, online erschienen am 24.07.2026. Verfasst von Mohamad Mahdi Osman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Hepatic encephalopathyLactuloseLiver cirrhosisPropensity scoreRifaximin
Autor:innen und Institutionen
- Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.
- Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic Foundation, Cleveland, OH, USA.
- Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, USA.
- Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic Foundation, Cleveland, OH, USA.
ORCID-Profile: Mohamad Mahdi Osman, Omar T Sims, Dian J Chiang
Zitieren
APA
Osman, M. M., Sims, O. T., & Chiang, D. J. (2026). Comparative Outcomes of Rifaximin Monotherapy and Lactulose in Cirrhosis: A Multicenter Cohort Study. Gut and Liver. https://doi.org/10.5009/gnl260099
Vancouver
Osman MM, Sims OT, Chiang DJ. Comparative Outcomes of Rifaximin Monotherapy and Lactulose in Cirrhosis: A Multicenter Cohort Study. Gut and Liver. 2026. doi:10.5009/gnl260099
BibTeX
@article{Osman2026,
author = {Osman, Mohamad Mahdi and Sims, Omar T and Chiang, Dian J},
title = {Comparative Outcomes of Rifaximin Monotherapy and Lactulose in Cirrhosis: A Multicenter Cohort Study},
journal = {Gut and Liver},
year = {2026},
doi = {10.5009/gnl260099}
}
EUVIMED